Skip to content
Open access

Plasma p-tau217 as a biomarker mapping cognitive impairment in Alzheimer's disease.

Nov 2026 · International Psychogeriatrics · pp. 100311 · 0 citations · 23 references
Medicine

Abstract

Objective

Plasma p-tau217 is a well-established biomarker of Alzheimer disease (AD) pathology, but its relationship with cognitive status and longitudinal cognitive change remains less well characterized. We investigated the clinical relevance of plasma p-tau217 as a blood-based biological correlate of cognitive status and change in AD.

Methods

We included 1147 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with available plasma biomarkers and amyloid-β (Aβ) status determined by amyloid PET or cerebrospinal fluid Aβ42. Cross-sectional associations between plasma p-tau217 and cognitive performance were evaluated across clinical stages and by Aβ status. Longitudinal associations between baseline plasma p-tau217 and subsequent cognitive change, as well as between changes in p-tau217 and changes in cognition, were assessed using linear mixed-effects models and correlation analyses. Baseline to last follow-up change correlations and separated within-person from between-person associations were also analyzed.

Results

Plasma p-tau217 were higher at more advanced clinical stages, particularly among Aβ+ participants. In the Aβ positive group, higher p-tau217 was associated with poorer baseline MMSE, CDR-SB, and ADAS-Cog13 scores (partial ρ = -0.46, 0.52, and 0.55, respectively). Higher baseline p-tau217 was associated with greater subsequent worsening on all three measures at nominal P < 0.05. Increases in p-tau217 were associated with concurrent worsening in ADAS-Cog13 and CDR-SB (P = 0.001 and P = 0.011, respectively, but not MMSE. Exploratory analyses identified a within-person association between p-tau217 increases and ADAS-Cog13 worsening. Associations were less consistent among Aβ- participants.

Conclusion

Plasma p-tau217 was associated with cognitive impairment and longitudinal cognitive change, particularly among Aβ+ participants. These findings support plasma p-tau217 as a potential blood-based biological correlate of cognitive status and longitudinal cognitive change in AD.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.